TRAIL Therapy for Rhabdomyosarcoma

横纹肌肉瘤的 TRAIL 疗法

基本信息

项目摘要

The proposal will elucidate critical regulators of the TRAIL signaling pathway that determine the exquisite sensitivity of 4/7 pediatric rhabdomyosarcomas (RMS) to TRAIL-induced cytotoxicity and apoptosis at concentrations < 1 ng/ml. All cultured cell lines express high levels of receptor DR5, but not DR4 or the decoy receptors DcR1 or DcR2, and express FADD and procaspase-8, with the exception of Rh36. Expression of c-FLIP is high in TRAIL-sensitive and -resistant lines, thereby not correlating directly with TRAIL sensitivity. Expression of procaspases-8 and -10 is highest in TRAIL-sensitive RD, Rh1 and Rh30. TRAIL-sensitive Rh18 expresses procaspase-8 in the absence of procaspase-10 and c-FLIP, and procaspase-10 is not expressed in TRAIL-resistant Rh41. Based upon these cellular characteristics the following hypotheses will be tested: 1) Following ligation of TRAIL to DR5, a DISC is formed among DR5, FADD, procaspase-8 and c-FLIP in RMS cell lines resulting in type I (direct) or type II (mitochondria- and procaspase-10- dependent) cell death, and 2) TRAIL resistance in Rh41 is due to deficiency in caspase-10. The second focus is to elucidate agents that can sensitize TRAIL- resistant RMS to TRAIL, or that can elicit synergistic interactions with TRAIL. Combination of TRAIL with actinomycin-D or doxorubicin has demonstrated > additive effects in TRAIL-sensitive RMS lines, and with recombinant human interferon-gamma (IFN-gamma) has induced cytotoxic response in TRAIL-resistant HT29 human .colon carcinoma cells. We will therefore test the following hypotheses: 1) TRAIL- resistant Rh28 and Rh41 can be sensitized to TRAIL by cycloheximide, actinomycin-D or IFN-gamma, and 2) specific chemotherapeutic agents can be identified that elicit synergistic interactions with TRAIL in TRAIL-sensitive RMS cell lines. Thirdly, we will test the hypothesis that TRAIL induces antitumor responses in human RMS xenografts when administered alone, or in combination with chemotherapeutic agents based upon data derived in tissue culture. The long-term objectives of the proposal are to develop highly effective therapy for metastatic disease in pediatric RMS from: 1) understanding specific signaling pathways involved in the regulation of cell death and apoptosis, 2) the identification of new molecular targets, and 3) developing new therapeutic strategies based upon specific molecular characteristics.
该提案将阐明TRAIL信号通路的关键调控因子,这些调控因子决定了4/7小儿横纹肌肉瘤(RMS)对TRAIL诱导的浓度< 1 ng/ml的细胞毒性和凋亡的敏感性。除Rh36外,所有培养的细胞系均表达高水平的DR5受体,但不表达DR4或诱饵受体DcR1或DcR2,并表达FADD和procaspase-8。c-FLIP在TRAIL敏感系和TRAIL抗性系中表达较高,因此与TRAIL敏感性无直接关系。procaspas8和-10在trail敏感的RD、Rh1和Rh30中表达最高。trail敏感的Rh18在缺乏procaspase-10和c-FLIP的情况下表达procaspase-8,而procaspase-10在trail抗性的Rh41中不表达。基于这些细胞特征,我们将验证以下假设:1)将TRAIL与DR5连接后,RMS细胞系中DR5、FADD、procaspase-8和c-FLIP之间形成DISC,导致I型(直接)或II型(依赖线粒体和procaspase-10)细胞死亡;2)Rh41中TRAIL的抗性是由于caspase-10的缺乏。第二个重点是阐明可以使TRAIL抗性RMS对TRAIL敏感的药物,或者可以引发与TRAIL的协同相互作用的药物。TRAIL与放线菌素- d或阿霉素联合在TRAIL敏感的RMS细胞系中显示出b>的加性效应,并且与重组人干扰素- γ (ifn - γ)联合在TRAIL耐药的HT29人中诱导了细胞毒性反应。结肠癌细胞。因此,我们将测试以下假设:1)TRAIL耐药的Rh28和Rh41可以通过环己烷酰亚胺、放线菌素- d或ifn - γ致敏TRAIL, 2)可以确定特异性化疗药物,在TRAIL敏感的RMS细胞系中引发与TRAIL的协同相互作用。第三,我们将根据组织培养的数据,验证TRAIL在单独给药或与化疗药物联合使用时诱导人类RMS异种移植物抗肿瘤反应的假设。该计划的长期目标是开发针对儿童RMS转移性疾病的高效治疗方法,包括:1)了解参与细胞死亡和凋亡调节的特定信号通路,2)确定新的分子靶点,以及3)基于特定分子特征开发新的治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JANET A. HOUGHTON其他文献

JANET A. HOUGHTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JANET A. HOUGHTON', 18)}}的其他基金

Targeting GLI-dependent Transcription by GANT61 in Colon Cancer
GANT61 在结肠癌中靶向 GLI 依赖性转录
  • 批准号:
    8884234
  • 财政年份:
    2015
  • 资助金额:
    $ 24.9万
  • 项目类别:
Targeting GLI-dependent Transcription by GANT61 in Colon Cancer
GANT61 在结肠癌中靶向 GLI 依赖性转录
  • 批准号:
    9033084
  • 财政年份:
    2015
  • 资助金额:
    $ 24.9万
  • 项目类别:
Development Therapy for Metastatic Colorectal Cancer
转移性结直肠癌的开发治疗
  • 批准号:
    7060749
  • 财政年份:
    2005
  • 资助金额:
    $ 24.9万
  • 项目类别:
Development Therapy for Metastatic Colorectal Cancer
转移性结直肠癌的开发治疗
  • 批准号:
    7226179
  • 财政年份:
    2005
  • 资助金额:
    $ 24.9万
  • 项目类别:
Development Therapy for Metastatic Colorectal Cancer
转移性结直肠癌的开发治疗
  • 批准号:
    6929464
  • 财政年份:
    2005
  • 资助金额:
    $ 24.9万
  • 项目类别:
TRAIL Therapy for Rhabdomyosacrcoma
横纹肌肉瘤的 TRAIL 疗法
  • 批准号:
    7578856
  • 财政年份:
    2001
  • 资助金额:
    $ 24.9万
  • 项目类别:
TRAIL Therapy for Rhabdomyosarcoma
横纹肌肉瘤的 TRAIL 疗法
  • 批准号:
    6331862
  • 财政年份:
    2001
  • 资助金额:
    $ 24.9万
  • 项目类别:
P53 GENE AND CHEMOSENSITIVITY
P53 基因和化学敏感性
  • 批准号:
    6500717
  • 财政年份:
    2001
  • 资助金额:
    $ 24.9万
  • 项目类别:
TRAIL Therapy for Rhabdomyosarcoma
横纹肌肉瘤的 TRAIL 疗法
  • 批准号:
    6633824
  • 财政年份:
    2001
  • 资助金额:
    $ 24.9万
  • 项目类别:
TRAIL Therapy for Rhabdomyosacrcoma
横纹肌肉瘤的 TRAIL 疗法
  • 批准号:
    7770818
  • 财政年份:
    2001
  • 资助金额:
    $ 24.9万
  • 项目类别:

相似海外基金

Regulation of mRNA homeostasis by PD-L1
PD-L1 对 mRNA 稳态的调节
  • 批准号:
    10622760
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
Glutathione and redox state of progesterone-regulated breast cancer stem cells
黄体酮调节的乳腺癌干细胞的谷胱甘肽和氧化还原状态
  • 批准号:
    9258301
  • 财政年份:
    2017
  • 资助金额:
    $ 24.9万
  • 项目类别:
Progression of Metastasis of Oral Tongue Cancer
口腔舌癌转移进展
  • 批准号:
    7051438
  • 财政年份:
    2003
  • 资助金额:
    $ 24.9万
  • 项目类别:
Progression of Metastasis of Oral Tongue Cancer
口腔舌癌转移进展
  • 批准号:
    6877955
  • 财政年份:
    2003
  • 资助金额:
    $ 24.9万
  • 项目类别:
Improved liver function and regeneration with A20
A20 改善肝功能和再生
  • 批准号:
    7173743
  • 财政年份:
    2003
  • 资助金额:
    $ 24.9万
  • 项目类别:
Progression of Metastasis of Oral Tongue Cancer
口腔舌癌转移进展
  • 批准号:
    6747312
  • 财政年份:
    2003
  • 资助金额:
    $ 24.9万
  • 项目类别:
Mechanisms Regulating Human Neutrophil Apoptosis
调节人类中性粒细胞凋亡的机制
  • 批准号:
    6782489
  • 财政年份:
    2001
  • 资助金额:
    $ 24.9万
  • 项目类别:
TRAIL Therapy for Rhabdomyosarcoma
横纹肌肉瘤的 TRAIL 疗法
  • 批准号:
    6862647
  • 财政年份:
    2001
  • 资助金额:
    $ 24.9万
  • 项目类别:
Nitric oxide ameliorates TNF-a or endotoxin/actinomycin D-induced apoptosis.
一氧化氮可改善 TNF-a 或内毒素/放线菌素 D 诱导的细胞凋亡。
  • 批准号:
    08457335
  • 财政年份:
    1996
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mechanisms of radiation-induced interphase death of thymocytes expressed as apoptosis
辐射诱导胸腺细胞间期死亡的机制表现为细胞凋亡
  • 批准号:
    61580184
  • 财政年份:
    1986
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了